NCT00583492View on ClinicalTrials.gov

Randomized Trial of Suicide Gene Therapy and Prostate Cancer

PHASE2CompletedINTERVENTIONAL
Enrollment

44

Participants

Timeline

Start Date

December 31, 2007

Primary Completion Date

September 30, 2013

Study Completion Date

September 30, 2013

Conditions
Prostate Cancer
Interventions
BIOLOGICAL

Ad5-yCD/mutTKSR39rep-ADP

Ad5-yCD/mutTKSR39rep-ADP (1 x 10\^12 vp) on day 1 Plus Radiation - 40 x 2 Gy for a total dose of 80 Gy or 44 x 1.8 Gy for a total dose of 79.2 Gy Plus 2 week course (weekdays only) of 5-FC and vGCV prodrug therapy

RADIATION

IMRT

40 x 2 Gy for a total dose of 80 Gy or 44 x 1.8 Gy for a total dose of 79.2 Gy

Trial Locations (2)

21231

Johns Hopkins University School of Medicine, Baltimore

48202

Henry Ford Health System, Detroit

All Listed Sponsors
lead

Henry Ford Health System

OTHER

NCT00583492 - Randomized Trial of Suicide Gene Therapy and Prostate Cancer | Biotech Hunter | Biotech Hunter